Rituximab's patent expired in 2015, and since then, biosimilars have flooded the market. The rituximab market research shows that biosimilars now hold over 70% of the market in some regions, driving prices down. In Europe, a biosimilar Rituximab can cost 50% less than the originator. That's huge for healthcare budgets.

What's the catch? Biosimilars are not generics — they're highly similar but not identical. The rituximab market trends highlight that subcutaneous administration is the fastest‑growing route, and many biosimilars are now available in this format, improving patient convenience.

But some doctors are hesitant to switch patients from originator to biosimilar, fearing immunogenicity or loss of efficacy. However, extensive switching studies show no difference in outcomes.

The bottom line: biosimilars are safe, effective, and cost‑saving. If you're prescribed Rituximab, don't be afraid of the biosimilar version. It's the same medicine, made by a different company.